REMARKS

Claims 1-24 are pending in the Application. The Examiner has made a restriction requirement, restricting the Claims into three groups, with Group I comprising Claims 1-10; Group II comprising Claims 11-17; and Group III comprising Claims 18-24.

To further business interests, Applicants have elected the Claims in Group II, *i.e.*, Claims 11-17 without traverse. Claims 1-10 and 18-24 are canceled herein without prejudice in view of the present restriction requirement. Applicants reserve the right to prosecute these claims in one or more Divisional Applications.

The Examiner has made a further restriction of the claims of Group II. The Examiner asserts that the "at least two CYP2D6 associated polymorphisms" recited in Claim 11 may be selected from the list of 32 different polymorphisms recited in dependent Claim 15, and requires restriction to a single combination of at least two. (Page 4). Applicants respectfully disagree. The general method of Claim 11 is not limited to the polymorphisms recited in Claim 15. The Examiner further asserts that the polymorphisms recited in Claim 15 possess different structural and functional characteristics and may not be substituted one for another. Again, Applicants respectfully disagree. Each of the recited sequences represents a polymorphic variation of CYP2D6 and, in the context of performing the claimed generic method comprising detecting at least two CYP2D6 polymorphic sequences, they are, in fact, interchangeable. Nonetheless, for business reasons, Applicants herein cancel Claims 15 and 17 without prejudice, rendering this restriction moot. Applicants reserve the right to prosecute the same or similar claims in one or more future applications.

If a telephone interview would aid in the prosecution of this application, Applicants encourage the Examiner to call the undersigned collect at (608) 218-6900.

Dated: May 23, 2006

Mary Ann D. Brow
Registration No. 42,363
MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105